Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has...
Pharmaceutical
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ETNEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG...
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d’une conférence web le 26 septembre à 14 h 00 CET
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14...
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming...
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company...
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This...
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage...
PHAXIAM Provides Business and Financial Update For the First Half of 2023
PHAXIAM Provides Business and Financial UpdateFor the First Half of 2023 Conference call and webcast (English) on Monday, September 25,...
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Cingulate Inc. to Present at the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 02:30 PM PTKANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a...
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST Liege, Belgium, September 21,...
Information on the total number of voting rights (denominator)
Information on the total number of voting rights (denominator) Liege, Belgium, 21 September 2023 – 5:45 pm CEST – Mithra...
LSL Pharma Group Announces Brokered Private Placement of Convertible Debentures of Up to $4,000,000
Debenture proceeds will provide additional funds and flexibility for growthBOUCHERVILLE, Québec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group...
U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits...
Skye Bioscience Announces Participation at Upcoming Investor Conferences
San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical...
Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance
No Immediate Effect on Nasdaq Listing or Trading of the Company's Common StockMONTREAL, QC / ACCESSWIRE / September 21, 2023...